In the last trading session, 1.53 million Cellectar Biosciences Inc (NASDAQ:CLRB) shares changed hands as the company’s beta touched 0.68. With the company’s per share price at $0.34 changed hands at $0.02 or 6.72% during last session, the market valuation stood at $15.52M. CLRB’s last price was a discount, traded about -1126.47% off its 52-week high of $4.17. The share price had its 52-week low at $0.22, which suggests the last value was 35.29% up since then. When we look at Cellectar Biosciences Inc’s average trading volume, we note the 10-day average is 2.07 million shares, with the 3-month average coming to 2.12 million.
Analysts gave the Cellectar Biosciences Inc (CLRB) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.50. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CLRB as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight.
Cellectar Biosciences Inc (NASDAQ:CLRB) trade information
Instantly CLRB was in green as seen at the end of in last trading. With action 6.89%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 12.64%, with the 5-day performance at 6.89% in the green. However, in the 30-day time frame, Cellectar Biosciences Inc (NASDAQ:CLRB) is 19.86% up. Looking at the short shares, we see there were 1.97 million shares sold at short interest cover period of 1.72 days.
The consensus price target for the stock as assigned by Wall Street analysts is 12, meaning bulls need an upside of 97.17% from its current market value. According to analyst projections, CLRB’s forecast low is 12 with 12 as the target high. To hit the forecast high, the stock’s price needs a -3429.41% plunge from its current level, while the stock would need to soar -3429.41% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 40.27%. The 2025 estimates are for Cellectar Biosciences Inc earnings to increase by 47.54%, but the outlook for the next 5-year period is at 16.51% per year.
CLRB Dividends
Cellectar Biosciences Inc is expected to release its next quarterly earnings report on 2025-Mar-12.
Cellectar Biosciences Inc (NASDAQ:CLRB)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.64% of Cellectar Biosciences Inc shares while 11.00% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 11.18%.
